All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings.
These reports are called 13F reports. However, the filings are required
the following quarter
from the reporting period,
which means that by the time the filing is made (and we see them), the information could be five months old.
For funds
with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover,
the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions
are identified in the table. However, they are not required to report short positions.
Click the link icon to see the full transaction history.
Upgrade
to unlock premium data and export to Excel
.
Security |
Imputed Share Price |
Prev Shares |
Current Shares |
Change (Percent) |
Prev Value (USD x1000) |
Current Value (USD x1000) |
Change (Percent) |
CBAY / CymaBay Therapeutics, Inc.
|
|
|
|
|
|
|
|
RLAY / Relay Therapeutics, Inc.
|
|
|
|
|
|
|
|
MDGL / Madrigal Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
INSM / Insmed Incorporated
|
|
|
|
|
|
|
|
IRON / Disc Medicine, Inc.
|
|
|
|
|
|
|
|
VRDN / Viridian Therapeutics, Inc.
|
|
|
|
|
|
|
|
HARP / Harpoon Therapeutics, Inc.
|
|
|
|
|
|
|
|
AVDL / Avadel Pharmaceuticals plc
|
|
|
|
|
|
|
|
RVMD / Revolution Medicines, Inc.
|
|
|
|
|
|
|
|
IOVA / Iovance Biotherapeutics, Inc.
|
|
|
|
|
|
|
|
CRNX / Crinetics Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
CGEM / Cullinan Therapeutics, Inc.
|
|
|
|
|
|
|
|
AXSM / Axsome Therapeutics, Inc.
|
|
|
|
|
|
|
|
OLMA / Olema Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
INZY / Inozyme Pharma, Inc.
|
|
|
|
|
|
|
|
GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
ITOS / iTeos Therapeutics, Inc.
|
|
|
|
|
|
|
|
FOLD / Amicus Therapeutics, Inc.
|
|
|
|
|
|
|
|
NTLA / Intellia Therapeutics, Inc.
|
|
|
|
|
|
|
|
VERV / Verve Therapeutics, Inc.
|
|
|
|
|
|
|
|
XERS / Xeris Biopharma Holdings, Inc.
|
|
|
|
|
|
|
|
MORF / Morphic Holding, Inc.
|
|
|
|
|
|
|
|
PHAT / Phathom Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
MLTX / MoonLake Immunotherapeutics
|
|
|
|
|
|
|
|
ALXO / ALX Oncology Holdings Inc.
|
|
|
|
|
|
|
|
GERN / Geron Corporation
|
|
|
|
|
|
|
|
KALV / KalVista Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
TVTX / Travere Therapeutics, Inc.
|
|
|
|
|
|
|
|
RPTX / Repare Therapeutics Inc.
|
|
|
|
|
|
|
|
KRTX / Karuna Therapeutics, Inc.
|
|
|
|
|
|
|
|
VKTX / Viking Therapeutics, Inc.
|
|
|
|
|
|
|
|
RGNX / REGENXBIO Inc.
|
|
|
|
|
|
|
|
HOWL / Werewolf Therapeutics, Inc.
|
|
|
|
|
|
|
|